MedTrace Logo

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

NCT05933187 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-11-24

No results posted yet for this study

Summary

The purpose of this trial is to evaluate plasma concentrations of emraclidine following single dose oral administration of different emraclidine immediate release (IR) tablets in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

Treatment A: Emraclidine 30mg IR tablets (reference)

IR oral tablets

DRUG

Treatment B: Emraclidine 30mg IR test tablets 1

IR oral tablets

DRUG

Treatment C: Emraclidine 30mg IR test tablets 2

IR oral tablets

DRUG

Treatment D: Emraclidine 30mg IR test tablets 3

IR oral tablets

Sponsors & Collaborators

  • Cerevel Therapeutics, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-19
Primary Completion
2023-09-12
Completion
2023-09-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05933187 on ClinicalTrials.gov